Key clinical point: For patients with metastatic non–small cell lung cancer (NSCLC) who have disease progression on immunotherapy, adding stereotactic body radiotherapy (SBRT) could improve progression-free survival (PFS).
Major finding: The disease control rate was 57.14%.
Study details: A prospective phase 2 trial involving 56 patients with metastatic non–small cell lung cancer (NSCLC).
Disclosures: The investigators disclosed relationships with Genentech, AstraZeneca, Merck, and others.
Campbell et al. ASTRO 2019. Abstract 74.